Nouveau Inc Announces Brian Shibley CEO of PURA as Interim CEO of NOUV
January 15 2019 - 12:04PM
InvestorsHub NewsWire
Nouveau
Inc Announces
Brian Shibley CEO of PURA as Interim CEO
of NOUV
Dallas, TX.
-- January 15, 2019 -- InvestorsHub NewsWire
-- Nouveau
Life Pharmaceuticals, Inc. (dba/Nouveau Inc.) (USOTC:
NOUV) ("NOUV") and Puration, Inc. (USOTC:
PURA)
("PURA") today announced
that
Brian
Shibley, the current CEO
PURA
has been
appointed as
the interim CEO of NOUV. On October
4, 2018, PURA sold its
cannabis cultivation business to NOUV in exchange for
a $1.2
million convertible
note with a commitment that the note would promptly be
converted into
shares of NOUV and that those converted shares would be distributed
in a stock dividend to the shareholders of PURA.
The
process of updating NOUV's public filings in order to proceed with
the dividend has taken longer than originally anticipated.
Brian Shibley's
appointment as
CEO is anticipated to reaccelerate the update of NOUV public
filings and in so doing, speed up the anticipated dividend of NOUV
shares to PURA shareholders.
"Shareholders of NOUV and PURA
can expect to see public fling updates this week," committed
Brian Shibley, the CEO of both companies. "I
will make sure through public announcements that shareholders are
kept abreast of the updates on a blow by blow basis. The
cultivation business acquired by NOUV is thriving and with the
recent legalization of hemp farming in the U.S. under the 2018 Farm
Act, shareholders can expect to see 100 acres of hemp planted this
spring adding to the existing cultivation operations.
Now we need to get
the NOUV corporate filings up to speed to reflect the caliber of
the current operations under NOUV. After all is in compliance, we
will initiate the effort of recruiting and engaging permanent
senior management."
For more
information visit http://www.purationinc.com
Disclaimer/Safe
Harbor:
This news
release contains forward-looking statements within the meaning of
the Securities Litigation Reform Act. The statements reflect the
Company's current views with respect to future events that involve
risks and uncertainties. Among others, these risks include the
expectation that any of the companies mentioned herein will achieve
significant sales, the failure to meet schedule or performance
requirements of the companies' contracts, the companies' liquidity
position, the companies' ability to obtain new contracts, the
emergence of competitors with greater financial resources and
the impact of
competitive pricing. In the light of these uncertainties, the
forward-looking events referred to in this release might not occur.
These statements have not been evaluated by the Food and Drug
Administration. These products are not intended to diagnose, treat,
cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800)
861-1350
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From Apr 2023 to Apr 2024